Athersys stem cell therapy disappoints in first efficacy trial in ulcerative … – MedCity News
| MedCity News Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis. But there’s another tranche of data coming later this summer … Athersys Inc. stem cell therapy for bowel disease fails to show ‘meaningful …Crain’s Cleveland Business Athersys stem–cell therapy for bowel disease fails in studyReuters Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For …WallStreetPR Wall Street Journal –Benzinga all 11 news articles |
